Meta Ads dashboards for Healthcare and Pharma campaigns report a CPC, a CPA, and a CVR that look complete, but none of them show what share of that spend actually reached a real patient or caregiver. Lunio's 2026 detection data adds that missing layer, measuring the invalid traffic that slips past Meta's own fraud filters in this exact vertical. Find out how much of your Meta Ads budget is being wasted →
Meta Ads Benchmarks for Healthcare / Pharma at a Glance
- Average CPC: Across Lunio-monitored Healthcare / Pharma Meta Ads accounts in 2026, the observed average CPC is $2.949 (n=2 accounts, directional). FDA fair balance requirements and Meta's Sensitive Health Topics policy restrict both creative and audience supply, which keeps Healthcare / Pharma CPCs structurally above cross-industry Meta Ads averages.
- CPM & CTR: Per AdLibrary.com's May 2026 Healthcare benchmarks, CPM runs $18 to $45 depending on sub-vertical and CTR sits at 0.6% to 1.4%, both below the cross-industry norm because compliance-constrained creative suppresses engagement signals. A CTR well above this range is often a sign of non-human clicks inflating the numerator rather than stronger creative.
- Invalid traffic rate: Healthcare / Pharma Meta Ads accounts show an observed IVT rate of 5.63% (n=2, directional, 2026), measuring invalid traffic that has already cleared Meta's native filters.
- Your hidden cost: At $2.949 CPC and 5.63% IVT, roughly $5.63 of every $100 spent reaches a non-human or otherwise invalid endpoint before a single patient ever sees your offer. Lunio runs a free 14-day traffic audit to show exactly where that spend is going. Calculate how much you're losing →
Meta Ads Benchmarks for Healthcare / Pharma: Overall Metrics
Healthcare / Pharma auctions on Meta Ads are shaped by narrow, geographically or demographically constrained audiences, HIPAA restrictions on patient data use in targeting, and FDA fair balance requirements that limit creative engagement. These structural pressures mean the benchmarks below should be read against a higher cost baseline than most cross-industry Meta Ads reporting assumes.
| Campaign Type | IVT Rate | CPC | CPM | CPA |
|---|---|---|---|---|
| Healthcare / Pharma, blended account average | 5.63% | $2.949 | $18–$45 | $20.87 |
No mobile vs. desktop split has been published specifically for Healthcare / Pharma on Meta Ads. In cross-vertical terms, mobile inventory is typically cheaper per click simply because it carries more volume, but healthcare's narrow, compliance-constrained targeting tends to offset much of that advantage, since the same small eligible audience is being bid on regardless of device.
Average CPC & CPM: Mobile vs. Desktop
Lunio's $2.949 CPC figure is a blended average across devices, not split by placement surface, so it should be read as the anchor figure for budget planning rather than a device-specific benchmark. Given the absence of a Healthcare-specific device split, the safest practitioner approach is to monitor CPC by device within Ads Manager directly and compare it against this blended figure rather than assuming a mobile discount that may not materialise once narrow targeting and compliance restrictions are factored in.
Additional Metrics: CTR, CVR, CPA/CPL & ROAS
ROAS is omitted from this page because no healthcare-specific Meta Ads ROAS figure exists in current benchmark research. HIPAA constraints on passing conversion value through the Pixel, and the fact that most healthcare conversions are leads rather than direct transactions, make ROAS structurally difficult to measure natively for this vertical.
| Metric | Average | Notes |
|---|---|---|
| CTR | 0.6%–1.4% | Per AdLibrary.com, May 2026. Reported CTR includes invalid clicks; a Healthcare / Pharma account reporting CTR materially above 1.4% alongside a soft CVR should be checked for invalid traffic rather than treated as a creative win. |
| CVR | 14.13% | n=1 account, directional only. With 5.63% of the click stream invalid, part of this reported efficiency may reflect leads or clicks originating from non-human sources, not stronger patient intent. |
| CPA/CPL | $20.87 | n=1 account, directional only. Adjusted for the observed 5.63% IVT rate, the effective media-only cost per real human lead rises to approximately $22.12. |
A Note on This Data
The CPC, IVT rate, CPA, and CVR figures above come from Lunio's detection engine running in monitor-only mode across real Healthcare / Pharma Meta Ads accounts throughout 2026. Sample sizes are small (n=2 for CPC and IVT rate, n=1 for CPA and CVR), so these figures should be treated as directional observations rather than statistically robust industry averages. CPM and CTR figures are drawn from AdLibrary.com's May 2026 sub-vertical research. For broader cross-platform IVT context, see the Lunio 2026 Global Invalid Traffic Report. Calculate how much you're losing →
Meta Ads Benchmarks for Healthcare / Pharma by Campaign Type & Placement
Healthcare / Pharma's relationship with Meta Ads campaign types is unusually constrained compared to other verticals, because Meta's 2025–2026 health data restriction tiers dictate which objectives and tracking methods are even available. Telehealth, pharma, and mental health advertisers typically fall under Meta's Full-Restricted classification, which blocks Pixel and Conversions API (CAPI) transmission of conversion events entirely, limiting them to awareness, engagement, and traffic objectives rather than conversion-optimised campaigns.
Lead Generation (Facebook Lead Ads): Lunio's blended data shows 5.63% IVT across Healthcare / Pharma Meta Ads accounts, but lead-gen campaigns specifically carry additional exposure. Per Lunio's analysis of invalid traffic inside Meta Ads, Meta's built-in lead forms pre-populate user data, which reduces the effort required for a bot to complete a "conversion" to a single tap, making native Lead Ads a common entry point for fake form fills that pollute patient intake pipelines.
Traffic & Awareness (common for pharma, telehealth, mental health): Advertisers forced into upper-funnel objectives by Full-Restricted classification should expect IVT exposure closer to the Meta Ads platform-level average, since their campaigns typically rely on broader targeting rather than precision retargeting that HIPAA and Meta's Sensitive Health Topics policy otherwise restrict.
Advantage+ (automated campaigns): Advantage+ relies on whatever conversion signal is available. For Healthcare / Pharma advertisers whose conversion tracking is already limited, any invalid clicks or fake conversions that do get through carry a disproportionate weight in how the algorithm learns to allocate budget.
Audience Network placement: Automatic placement settings, the default under Advantage+, include Audience Network alongside Feed and Stories. Per Lunio's platform-level IVT analysis, partner and off-platform inventory typically carries higher invalid traffic exposure than native Feed or Stories placements, and advertisers have limited ability to fully exclude it under automated placement settings. Healthcare advertisers optimising for lead quality over reach should review placement-level performance and consider restricting Audience Network where CPL spikes are unexplained.
These restrictions were driven in part by FTC enforcement against GoodRx ($1.5M, February 2023), BetterHelp ($7.8M, August 2023), and Cerebral ($7M+, April 2024) over health data sharing through tracking pixels, which is useful context for any practitioner wondering why their conversion tracking options narrowed in the first place.
Meta Ads Benchmarks for Healthcare / Pharma by Country & Region
| Country | IVT Rate |
|---|---|
| United States | 8.44% |
| United Kingdom | 7.97% |
| Australia | 7.87% |
| France | 6.63% |
| Germany | 6.34% |
| Canada | 6.29% |
These are cross-vertical, all-platform IVT rates, since no country-level figure exists specifically for Healthcare / Pharma on Meta Ads. The United States combines the highest IVT exposure (8.44%) with the highest healthcare CPC and CPM ranges cited by AdLibrary.com, making it the clearest double-risk market for Healthcare / Pharma advertisers running Meta Ads. Canada (6.29%) and Germany (6.34%) sit at the lower end of IVT exposure among these markets, offering relatively more efficient conditions. See Lunio's ad fraud data by country for the full breakdown across markets and platforms.
How Much of Your Meta Ads Budget Is Being Wasted on Invalid Traffic?
Meta's native systems catch and filter General Invalid Traffic (GIVT), known bots, data centre traffic, and crawlers, effectively. The 5.63% IVT rate observed across Healthcare / Pharma Meta Ads accounts in 2026 represents Sophisticated Invalid Traffic (SIVT): clicks and form submissions that mimic human behaviour closely enough to clear Meta's filters. These two measurements are additive, not competing. Meta catches what it catches, and 5.63% still gets through.
Run the maths on a typical regional healthcare advertiser spending $500,000 annually on Meta Ads: at a 5.63% IVT rate, approximately $28,150 of that budget reaches invalid traffic every year, equivalent to roughly 9,545 invalid clicks at the observed $2.949 CPC. Because Healthcare / Pharma on Meta Ads is overwhelmingly a lead-generation vertical rather than a transactional one, exposure is likely structurally higher still: per Lunio's Meta Ads invalid traffic analysis, lead-gen campaigns experience 32.07% higher average IVT rates than transactional models, since bots can fake a form fill far more easily than a verified purchase.
Travel platform Much Better Adventures saw this pattern directly on Meta: low CPCs and low cost-per-landing-page-view that masked high bounce rates and weak downstream conversion. An A/B test confirmed a 68.29% reduction in invalid traffic, a 12.16% decrease in CPA, and a 4% increase in conversion rate once that traffic was identified and excluded. The lesson translates directly to healthcare lead gen: a healthy-looking CPL can still be hiding a patient intake pipeline full of leads that were never real.
The figures above are calculated at the observed 5.63% IVT rate and $2.949 CPC from Lunio's 2026 Healthcare / Pharma detection data. Your account's actual exposure depends on your placement mix, campaign type, and sub-vertical, and the only way to measure it precisely is to run a traffic audit against your own live campaign data.
Start your free 14-day traffic audit with Lunio →
Calculate Your Wasted Ad Spend
60 seconds, no signup. Built on Lunio's analysis of 2.7B+ ad clicks. Find out your industry's invalid traffic rate, your wasted spend, and the revenue you could recover.
from your business every year. That's $0 every month walking out the door — and another $0 every day you don't act.
Run a free 14-day audit on your live account and see your real numbers — broken down by campaign, keyword, geo and domain.
Calculations based on Lunio's Global Invalid Traffic Report 2026. Eight industries shown use Lunio-measured rates; additional industries use Lunio-methodology estimates calibrated against comparable verticals. Lost revenue applies Lunio's conservative 3:1 ROAS baseline — every $1 of wasted ad spend equals roughly $3 in missed revenue. Actual results vary by account.
Meta Ads Benchmarks for Healthcare / Pharma: Why the Numbers Are Only Half the Story
Benchmarks tell you what you paid. They don't tell you what you got. A Healthcare / Pharma account that matches every figure on this page can still be losing real patient pipeline to invalid clicks and fake form fills that never show up as a line item anywhere except a patient appointment calendar that stays emptier than it should. The gap between those two pictures is exactly what Lunio's invalid traffic data is built to close, account by account rather than industry average by industry average.
Start your free 14-day traffic audit with Lunio →
FAQ
What is the average CPC for Healthcare / Pharma on Meta Ads?
Lunio's 2026 detection data observed an average CPC of $2.949 across Healthcare / Pharma Meta Ads accounts (n=2, directional). This sits well above WordStream's often-cited $1.32 figure, which is based on 2016–2017 advertiser data and should not be treated as a current benchmark. It falls within AdLibrary.com's May 2026 range for dental and telehealth sub-verticals ($2.80–$7), though pharma-specific campaigns can run considerably higher.
What's a good CTR for Meta Ads in Healthcare / Pharma, and when is a high CTR a warning sign?
Per AdLibrary.com's May 2026 data, Healthcare CTR on Meta Ads typically runs 0.6% to 1.4%, with pharma and medical device creative at the low end due to FDA fair balance constraints. A CTR significantly above this range, especially paired with a weak conversion rate, is often a sign that invalid clicks are inflating the click count rather than evidence of stronger creative performance.
How does invalid traffic affect my Meta Ads benchmarks?
Invalid traffic inflates CTR and CVR by adding non-human activity into the numerator while also raising your effective cost per real result. At Lunio's observed 5.63% IVT rate, the $2.949 reported CPC becomes approximately $3.12 once only real human clicks are counted, and the $20.87 reported CPA becomes approximately $22.12 on the media side alone. Invalid conversions also feed into Advantage+ and other automated bidding systems, teaching them to find more users who resemble the invalid traffic rather than real patients.
How do Meta Ads IVT rates differ between the US and Europe?
Across all verticals and platforms, the United States carries the highest IVT rate among major healthcare markets at 8.44%, followed by the United Kingdom at 7.97% and Australia at 7.87%. European markets such as Germany (6.34%), France (6.63%), and Canada (6.29%) run lower, meaning US-focused Healthcare / Pharma advertisers on Meta Ads face materially higher invalid traffic exposure than their European counterparts at comparable spend levels.
Table of Contents
On average, 8.51% of your ad budget is wasted.
But that number can be much higher. Find out how much you're spending on bot traffic.
%20The%20Complete%202026%20Definition%2c%20Types%2c%20and%20Detection%20Guide.png?width=600&name=What%20Is%20Invalid%20Traffic%20(IVT)%20The%20Complete%202026%20Definition,%20Types,%20and%20Detection%20Guide.png)
